MIP monitors immune response from a drop
of blood
The MIP panel measures a patient’s relative expression of 51 immune system-related genes within 12 immune system expression modules.
Type-1 Interferon (IFN-1) |
|
IFN-1 status is a prognostic factor for disease severity in SLE, including risk of progression to Lupus Nephritis. Many current and developmental therapeutics target IFN-1 and the JAK/STAT pathway and related pathways. |
Type-2 Interferon (IFN-γ) |
|
IFN-γ plays a key role in T-cell differentiation, immunoregulatory, antiviral and anti-tumor activity. This 3-gene module is being evaluated for therapy response and disease activity in SLE, subtyping in RA, and immunotherapy response prediction in cancer. |
B-Cell |
|
Many common immunosuppressive therapies function through a B-cell depletion mechanism including Rituximab, Ocrevus, and Benlysta. The B-cell module can be used to monitor therapeutic response for B-cell depleting therapies. |
Plasmablast/Plasma Cell |
|
This module has been shown to positively correlate with disease activity in SLE and is impacted by B-cell depleting therapies. Measuring these changes may aid clinicians in the early identification of changes in disease activity or potential disease flare. |
Neutrophils/Low Density Granulocytes (LDGs) |
|
Low density granulocytes are a subset of neutrophils that have been implicated in SLE inflammation and disease progression, including promoting organ damage and increased production of Type-1 Interferon. |
T-Cells |
|
The T-cell genes in MIP are looked at individually to help better understand the underlying mechanism of a patient’s autoimmune disease or cancer. |
T-Cell Exhaustion |
|
In chronic autoimmune disease like SLE, the process of T-cell exhaustion helps inhibit immune response, and exhausted T-cell responses have been associated with better outcomes. T-cell exhaustion mechanisms and markers also play a major role in cancer and how tumors hide from the immune system. |
Partnering to achieve a common goal